Marcia Simpson Brose

faculty photo
Associate Professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania
Member, University of Pennsylvania Center for Research on Reproduction and Women’s Health
Member, Abramson Cancer Center of the University of Pennsylvania
Member, Clinical Trials Scientific Review and Monitoring Committee
Member, Medical Scientist Training Program Admissions Committee
Director, Head and Neck Clinical Trials, Department of Otorhinolaryngology: Head and Neck Surgery
Director, Thyroid Cancer Therapeutics Program, Department of Otorhinolaryngolgy: Head and Neck Surgery
Member, American Cancer Society, Internal Review Group (ACS IRG)
Vice Chair, Clinical Trials Scientific Review and Monitoring Committee (CTSRMC), Abramson Cancer Center
Member, Department of Otorhinolarynglogy: Head and Neck Cancer Scientist Search Committee
Department: Otorhinolaryngology: Head and Neck Surgery

Contact information
Stellar Chance Building 8M

422 Curie Blvd.
Philadelphia, PA 19104
Office: 215-746-6344
Fax: 215-898-2136
Graduate Group Affiliations
B.A. (Biology)
Amherst College, Amherst, MA, 1986.
Ph.D. (Genetics and Developmental Biology)
Rockefeller University, New York, NY, 1994.
M.D. (Medicine)
Cornell University Medical College, New York, NY, 1995.
Permanent link

Description of Research Expertise

Dr Brose is the director of the Thyroid Cancer Therapuetics Program and is a global leader in the development of the new field of thyroid cancer oncology. Her Phase II clinical trial of sorafenib in patients with advanced thyroid cancer lead to the successful completion of the first Phase III study, in this disease group (RAI refractory thyroid cancer). She was also one of the top accuers and lead site for the Phase III trial of cabozantinib for advance medullary thyroid cancer, which lead to FDA approval of this agent in November of 2012. Requested to speak and teach worldwide on her experience in the the use of novel agents to treat patients with all types of advanced thyroid cancer (Differentiate, Medullary, and Anaplastic), she is a global leader and educator to physicians and patients alike.

Dr. Brose also runs a lab in the field of translational studies in cancer genetics and genomics. Dr. Brose’s basic science research interest involves the identification of genetic abnormalities in the tumors of patients undergoing targeted therapies. Most of her research centers on translational projects directly related to samples obtained in the course of her clinical trial program. However, occasionally, science leads to leads in other tumor types. She currently has projects underway in thyroid cancer, breast cancer, lung cancer, colon cancer and esophageal cancer. Once identified, she is interested in understanding if these changes may identify tumors that may have or lack resistance to certain compounds. She has experience in the use of mice, drosophila, human tissue culture and clincal tissue samples. Her analytic tools include all types of PCR, RT-PCR, as well as the use of array comparative genomic hybridization (aCGH) and transcription profiling, taqman analysis, Q-RT-PCR and DNA sequencing on a regular basis, and whole and targeted genome sequencing. She also uses high resolution expression and SNP genotyping tetchnologies (Affymetrix and Illumina) to study the genetic basis of cancer. Dr. Brose provides the key correlative science for ongoing phaseI/II/III clinical trials at the University and internationally.

Description of Other Expertise

Dr. Brose regularly instructs and mentors medical students,Internal Medicine and Head and Neck Surgerical residents, fellows (Hematology/Oncology, and Head and Neck Surgery) and post-doctoral PhD fellows who rotate through her lab in Hematology/Oncology and Cell genetics

Description of Itmat Expertise

Dr Brose studies cancer genetics and genomics, with particular interest in the genetic changes that occur in cancer cells from cell culture, to changes found in patient tumor tissue, to responses observed in clinical trials, focusing mostly on thyroid cancer projects, but other rare cancers as well.

Selected Publications

Mark Yarchoan, M., Ma,C, Troxel, A.B., Stopenski, S.J., Tang, W., Cohen, A.B. Pappas-Paxinos, M., Johnson, B.A., Chen, E.Y., Feldman, M.D., Brose, M.S. : pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer Hormones and Cancer. Hormones and Cancer In Press 2016.

Yarchoan M, LiVolsi VA, Brose MS.: Reply to C. Bal et al and M. Xing. J Clin Oncol. 2015 Aug 1;33(22):2483. 33(22): 2483, August 2015 Notes: Epub 2015 Jun 29.

Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD.: Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 33(7): 786-809, March 2015.

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI.: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7): 621-630, February 2015.

Brose MS, Schlumberger M, Peña C, Kappeler C: Sorafenib for patients with differentiated thyroid cancer--authors' reply. Lancet 385(9964): 228-229, January 2015.

Yarchoan M, LiVolsi VA, Brose MS: BRAF mutation and thyroid cancer recurrence. J Clin Oncol. 33(1): 7-8, January 2015.

Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI.: A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 24(10): 1508-1514, October 2014.

Cohen AB, Brose MS: Second-line treatment for advanced thyroid cancer: an indication in need of randomized clinical trials. J Clin Endocrinol Metab. 99(6): 1995-7, June 2014.

Brose,M.S., Nutting,C.M., Jarzab, B., Elisei, R., Siena, S., Bastholt,L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, YK, Sherman, SI, Smit, JWA, Chung, J., Kappeler, C., Pena, C., Molnar, I., Schlumberger, M.J., on behalf of the DECISION Investigators*: Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase III trial. The Lancet 14: 60421-9, April 2014 Notes: Corresponding Author.

Brose,M.S., Frenette,C.T., Keefe, S.M., Stein, S.M.: Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective. Seminars in Oncology 41(1): S1-S16, February 2014.

back to top
Last updated: 02/05/2016
The Trustees of the University of Pennsylvania